Tags

Type your tag names separated by a space and hit enter

[A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
Rev Soc Bras Med Trop. 1999 Jul-Aug; 32(4):383-7.RS

Abstract

Efficacy and safety of meglumine antimoniate and sodium stibogluconate BP 88R were compared in cutaneous leishmaniasis treatment in Corte de Pedra, Bahia, an endemic area of leishmaniasis due to Leishmania (Viannia) braziliensis. An open trial was developed with one hundred twenty seven patients who were diagnosed based on clinical criteria and Montenegro's skin test. Fifty eight patients were treated with meglumine antimoniate and 69 received sodium stibogluconate. Both groups received 20 mg/Sbv/kg/day for 20 days. Patients were followed every ten days during treatment and every month thereafter for three months. Sixty two percent patients cured with meglumine antimoniate and 55% cured with sodium stibogluconate (p = 0.42). Headache was more frequent during the first half of treatment in patients receiving sodium stibogluconate (p = 0.026). During the second half, patients treated with sodium stibogluconate showed a greater frequency of myalgia/arthralgia (p = 0.004) and abdominal pain/anorexia (p = 0.004). Three patients treated with sodium stibogluconate had severe side effects.

Authors+Show Affiliations

Núcleo de Medicina Tropical e Nutrição, Universidade de Brasilia, Brasil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

por

PubMed ID

10495667

Citation

Saldanha, A C., et al. "[A Comparative Study Between Sodium Stibogluconate BP 88R and Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. I. the Efficacy and Safety]." Revista Da Sociedade Brasileira De Medicina Tropical, vol. 32, no. 4, 1999, pp. 383-7.
Saldanha AC, Romero GA, Merchan-Hamann E, et al. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety]. Rev Soc Bras Med Trop. 1999;32(4):383-7.
Saldanha, A. C., Romero, G. A., Merchan-Hamann, E., Magalhães, A. V., & Macedo, V. d. e. . O. (1999). [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety]. Revista Da Sociedade Brasileira De Medicina Tropical, 32(4), 383-7.
Saldanha AC, et al. [A Comparative Study Between Sodium Stibogluconate BP 88R and Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. I. the Efficacy and Safety]. Rev Soc Bras Med Trop. 1999 Jul-Aug;32(4):383-7. PubMed PMID: 10495667.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety]. AU - Saldanha,A C, AU - Romero,G A, AU - Merchan-Hamann,E, AU - Magalhães,A V, AU - Macedo,V de O, PY - 1999/9/25/pubmed PY - 1999/9/25/medline PY - 1999/9/25/entrez SP - 383 EP - 7 JF - Revista da Sociedade Brasileira de Medicina Tropical JO - Rev Soc Bras Med Trop VL - 32 IS - 4 N2 - Efficacy and safety of meglumine antimoniate and sodium stibogluconate BP 88R were compared in cutaneous leishmaniasis treatment in Corte de Pedra, Bahia, an endemic area of leishmaniasis due to Leishmania (Viannia) braziliensis. An open trial was developed with one hundred twenty seven patients who were diagnosed based on clinical criteria and Montenegro's skin test. Fifty eight patients were treated with meglumine antimoniate and 69 received sodium stibogluconate. Both groups received 20 mg/Sbv/kg/day for 20 days. Patients were followed every ten days during treatment and every month thereafter for three months. Sixty two percent patients cured with meglumine antimoniate and 55% cured with sodium stibogluconate (p = 0.42). Headache was more frequent during the first half of treatment in patients receiving sodium stibogluconate (p = 0.026). During the second half, patients treated with sodium stibogluconate showed a greater frequency of myalgia/arthralgia (p = 0.004) and abdominal pain/anorexia (p = 0.004). Three patients treated with sodium stibogluconate had severe side effects. SN - 0037-8682 UR - https://www.unboundmedicine.com/medline/citation/10495667/[A_comparative_study_between_sodium_stibogluconate_BP_88R_and_meglumine_antimoniate_in_the_treatment_of_cutaneous_leishmaniasis__I__The_efficacy_and_safety]_ DB - PRIME DP - Unbound Medicine ER -